Tag Archives: Biotech Cannabis

Creating Medicine from Cannabis

Cannabis’s unique medicinal properties and Active Compounds are widely documented. Cannabinoids interact within the Endocannabinoid System. THC has proven medical benefits in particular formulations. The Food and Drug Administration (FDA) has approved THC-based medications, dronabinol and nabilone, prescribed in pill form for nausea and appetite treatment, aiding cancer and AIDS patients.

In addition, several other cannabis -based medications have been approved or are undergoing clinical trials. Nabiximols, a mouth spray that is currently available for treating the spasticity and neuropathic pain that may accompany multiple sclerosis, combines THC with CBD.

The FDA also approved a CBD-based liquid medication called Epidiolex® for the treatment of severe childhood epilepsy, specifically, Dravet syndrome and Lennox-Gastaut syndrome. The medication is being delivered with reliable dosage and reproducible route.

Cannabis posses nitrogenous compounds, amino acids, proteins, glycoproteins, enzymes, sugars and related compounds, hydrocarbons, alcohols, acids, esters, aldehydes, ketones, fatty acids, lactones, steroids, terpenes, non-cannabinoid phenols, flavonoids, vitamins and pigments already used in Botanical Medicine and are yet to be empirically proven and peer reviewed. While some of these compounds are found in other Botanical Sources, it is likely that there are unique combinations found only in cannabis.

As we study this remarkable plant further, more constituents are showing promise for new and revolutionary Drug Delivery systems and Antibacterial Activities

Clearly, more research is needed from the scientific community to produce appropriate, safe utilization of cannabis. However, the FDA does not recognize the use of medical applications of cannabis. There is no reason to regulate cannabis derived medicine any different than general recommendations on studying botanicals.

Convoluted regulation of cannabis makes funding for research lacking. Independent Cannabis research cannot be done by companies as they are hindered from scaling and acquiring credit. In addition, concerns over conflicts of interest as seen with traditional drug company-sponsored studies.

In order to unlock cannabis potential cannabis possession should be deregulated so academic institutions can dedicate lab time for cannabis research.

Digital Channels need to be more lenient to discussion and allow ideas to spread and be refined. Unjustified resistance to cannabis for medical and recreational use has to be discarded. It is time regulative, communication and banking systems reform their attitude towards cannabis. As a global community we have proved that we can work fast if necessary. If you are interested in sharing cannabis related ideas or identify potential collaborations feel free to contact us privately.

Make sure you sign up to stay updated on groundbreaking research.